Drug Search Results
More Filters [+]

Emricasan

Alternative Names: emricasan, idn-6556
Latest Update: 2024-07-05
Latest Update Note: News Article

Product Description

Mechanisms of Action: CAAP Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Histogen
Company Location: San Diego CA 92121
Company CEO: Steven J. Mento
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Emricasan

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Hepatitis A|Type 1 Diabetes|Hepatitis C, Chronic|Hepatitis, Alcoholic|Hepatic Insufficiency|Liver Cirrhosis|Liver Failure, Acute|Acute-On-Chronic Liver Failure|Hepatitis, Chronic|Liver Cirrhosis, Alcoholic|Hypertension, Portal|Non-alcoholic Steatohepatitis|End Stage Liver Disease|Fatty Liver, Alcoholic|Cholestasis|Liver Diseases, Alcoholic|Liver Transplant|Hepatitis|Hepatocellular Carcinoma

Phase 1: Intestinal Diseases|COVID-19|Kidney Diseases

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

EMR-COV-PR001

P1

Terminated

COVID-19

2021-05-28

70%

ENCORE-LF

P2

Unknown status

Liver Cirrhosis

2019-08-01

23%

CON-EX-0217

N/A

Terminated

Liver Cirrhosis

2019-07-15

NCT02960204

N/A

Completed

Hepatitis, Alcoholic|Non-alcoholic Steatohepatitis|Hypertension, Portal|Fatty Liver, Alcoholic|Liver Cirrhosis, Alcoholic

2019-04-08

Recent News Events